InsightRX’s Precision Medicine technology to help improve care for patients undergoing stem cell transplants

Cloud-based precision dosing platform supports safer, more effective delivery of busulfan, fludarabine and antithymocyte globulin to patients at Memorial Sloan Kettering Cancer Center

SAN FRANCISCO, November 22, 2021 /PRNewswire/ — InsightRX, which provides a cloud-based precision dosing platform to help guide treatment decisions, today announced that Memorial Sloan Kettering Cancer Center (MSK) has implemented its precision dosing platform to improve the dosing of certain chemotherapy and immunosuppressants used in the delivery of stem cell transplants. to patients with haematological malignancies and other cancers.

InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care. The platform uses patient-specific data, pharmacological models and machine learning to understand each patient’s unique pharmacological profile and integrates seamlessly into a clinical workflow. (PRNews photo/InsightRX)

The InsightRX Nova platform helps select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressive anti-thymocyte globulin (ATG), for adult and pediatric patients undergoing stem cell transplants.

Stem cell transplants are typically preceded by a chemotherapeutic conditioning regimen that destroys cancer cells and suppresses a patient’s immune response to the donor cells. The dose required to achieve desired drug exposure is not standardized and differs based on individual patient factors such as weight, height, underlying health, metabolism, and prior drug levels.

Precision dosing is critical to maximizing the effectiveness of conditioning regimens, which have a “close therapeutic window” because their dose must be high enough to prevent disease relapse or graft failure, but low enough to prevent harmful side effects. In the case of busulfan and fludarabine, these can include life-threatening conditions such as sinusoidal obstruction syndrome (SOS), which damages the liver, and acute graft-versus-host disease (aGvHD), which occurs when donor cells attack the host’s organs and tissues after a stem cell transplant. The five-year cumulative death rate for leukemia patients receiving stem cell transplants is approximately 50%, with relapse, infection and GvHD as the leading causes of death.

“We are proud to partner with Memorial Sloan Kettering as it continues to innovate in cancer treatment and research to improve care and outcomes for patients,” said Sirj Goswami, PhD, CEO and co-founder of InsightRX. “This reflects a growing focus on expanding precision medicine beyond selecting targeted drugs to ensure that every patient receiving complex drugs is getting the right dose for them.”

The cloud-based InsightRX Nova precision dosing platform uses patient-specific data, pharmacokinetic/pharmacodynamic (PK/PD) models, and Bayesian forecasting to understand a patient’s unique pharmacological profile and guide treatment decisions.

A second-generation Bayesian pharmacokinetic (PK) model co-developed by InsightRX and researchers at the University of California, San Francisco (UCSF), demonstrated unprecedented accuracy and precision in achieving busulfan dosing targets in a 2020 study of busulfan conditioning prior to hematopoietic stem cell transplants (HCTs) for myeloid cancers such as chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).

The InsightRX Apollo real-time analytics platform captures and reports clinical and operational metrics to drive pharmacy quality improvement efforts.

About InsightRX
InsightRX is a healthcare technology company that has developed a cloud-based precision medicine and clinical analytics platform designed to individualize treatment at the point of care. The platform uses patient-specific data, pharmacological models and machine learning to understand each patient’s unique pharmacological profile and integrates seamlessly into a clinical workflow. Learn more about InsightRX’s recently announced $10 million Series A financing.

Media contact
Megan Moriarty
Amendola Communications for InsightRX
913.515.7530
mmoriarty@acmarketingpr.com

decide

decide

View original content to download multimedia: https://www.prnewswire.com/news-releases/insightrxs-precision-medicine-technology-to-help-improve-care-for-patients-receiving-stem-cell-transplants- 301430083 .html

SOURCE InsightRX

Leave a Comment